Abstract 7090: Preclinical characterization of ABSK211: A highly potent, orally bioavailable and selective pan-KRAS inhibitor with broad and robust activity in KRAS-driven tumors
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Yongxian Zhang, Fei Yang, Zhigang Feng, Meimei Sun, Xinyan Huang, Haibing Deng, Hongping Yu, Haiyan Ying
Institution: Abbisko Therapeutics Co., Ltd. (China)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7148765063
Cites:
Cited by:
Related to: